Enzolytics Inc (ENZC)

[foxi]

Some of these comparisons are apples and oranges.

KLXE is oil and gas, not biotech.
CMRA is biotech and new to NASDAQ as of May 20. There's often a price spike at uplisting.
SCOR is information and analytics, not biotech.
NMRK is real estate services, not biotech.
AGLE is biotech but looks to be struggling. Strong dilution, several FDA setbacks, & may be unprofitable for at least three more years.

A better comparison would be against OTC biotechs, and preferably those that develop products for immune modulation or treatments relating to immune disorders. Some of these have charts that somewhat align with ENZC's chart - for example, RGBP is down 95% and NWBO is down 72% since their respective 52 week highs. But these companies still have their own management, material events, technologies and financial situations which differ from ENZC's.

ENZC has only broadcasted good news, and shows zero new dilution on the books since its 52 week high. Without an uplist to QB/QX, they don't have an OTC requirement for timely disclosure of material events, which works against the company when shareholders discover setbacks like lawsuits, terminated partnerships or broken equipment after months of speculation and hype around information that later proves to be stale or incomplete. The company's continual failure to deliver its 2 year audit, and its recent shift toward more limited news / NDAs with all partners, further complicates this lack of transparency with investors and sets us up for further price decline if the company can't deliver on its hype.

No Dilution has occurred since October 15, 2020, when the total issued reached 2,797,935,953. Float has increased as shareholders who were issued original issuance of ENZC shares met the SEC requirements for removing the restrictive legends and obtained an opinion letter from a SEC approved attorney acceptable to the Transfer Agent representing the Company. With each increase in Float the total Restricted shares decreased in the same amount.

https://www.otcmarkets.com/otcapi/company/financial-report/323613/content

Earlier dilution has come into play since the all time high, in the form of Restricted shares flipped to Unrestricted, and has had a strong dilutive effect as many of these freshly unrestricted ENZC shares are believed to have been dumped into the market. Though this was primarily a factor in 2021, it's possible some parties still have shares to sell since traceability mostly ends once the shares are made Unrestricted.

Total float at December 31, 2020 was 1,670,830,512.

With each increase in Float the total Restricted shares decreased in the same amount.

Date | Shares Outstanding | Float | Restricted Shares
12/31/20 | 2,797,935,953 | 1,670,830,512 | 1,127,105,441
03/31/21 | 2,797,935,953 | 1,880,313,464 | 917,622,489
06/30/21 | 2,797,935,953 | 2,141,602,954 | 656,332,999
09/30/21 | 2,797,935,953 | 2,288,596,368 | 509,339,585
12/31/21 | 2,797,935,953 | 2,346,646,388 | 451,289,565

All quotes from https://www.otcmarkets.com/otcapi/company/financial-report/323613/content